How BioMarin Pharmaceutical makes money

Period

FY2025

How does BioMarin Pharmaceutical make money? This Sankey traces every dollar of revenue through the income statement — into cost of revenue, R&D, SG&A, and taxes — and shows what's left as profit. Pick any fiscal year, recent quarter, or the trailing twelve months. Straight from SEC filings.

BioMarin Pharmaceutical Inc. · FY2025 · year ended 2025-12-31

Revenue$3.2BGross profit$2.5B · 78%Cost of revenue$717M · 22%Operating income$409M · 13%Operating expenses$2.1B · 65%R&D$922M · 29%SG&A$1.2B · 36%Other opex$19M · 1%Pre-tax income$482M · 15%Other income$73M · 2%Net income$349M · 11%Income tax$134M · 4%VOXZOGO$927M · 29%VIMIZIM$792M · 25%NAGLAZYME$485M · 15%PALYNZIQ$433M · 13%ALDURAZYME$209M · 6%BRINEURA$186M · 6%KUVAN$100M · 3%Royalty & Other$53M · 2%ROCTAVIAN$36M · 1%

Each fiscal year from SEC filings. Percentages are share of revenue, so the green profit nodes read directly as gross / operating / net margin. Line items a company doesn't break out are derived from their siblings so the flows balance; small residuals show as “Other.” For informational purposes only.